Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 3
2013 1
2017 3
2018 2
2019 4
2020 9
2021 33
2022 20
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.
Mudd PA, Minervina AA, Pogorelyy MV, Turner JS, Kim W, Kalaidina E, Petersen J, Schmitz AJ, Lei T, Haile A, Kirk AM, Mettelman RC, Crawford JC, Nguyen THO, Rowntree LC, Rosati E, Richards KA, Sant AJ, Klebert MK, Suessen T, Middleton WD; SJTRC Study Team; Wolf J, Teefey SA, O'Halloran JA, Presti RM, Kedzierska K, Rossjohn J, Thomas PG, Ellebedy AH. Mudd PA, et al. Among authors: o halloran ja. Cell. 2022 Feb 17;185(4):603-613.e15. doi: 10.1016/j.cell.2021.12.026. Epub 2021 Dec 23. Cell. 2022. PMID: 35026152 Free PMC article.
Germinal centre-driven maturation of B cell response to mRNA vaccination.
Kim W, Zhou JQ, Horvath SC, Schmitz AJ, Sturtz AJ, Lei T, Liu Z, Kalaidina E, Thapa M, Alsoussi WB, Haile A, Klebert MK, Suessen T, Parra-Rodriguez L, Mudd PA, Whelan SPJ, Middleton WD, Teefey SA, Pusic I, O'Halloran JA, Presti RM, Turner JS, Ellebedy AH. Kim W, et al. Among authors: o halloran ja. Nature. 2022 Apr;604(7904):141-145. doi: 10.1038/s41586-022-04527-1. Epub 2022 Feb 15. Nature. 2022. PMID: 35168246 Free PMC article.
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, Lei T, Thapa M, Chen RE, Case JB, Amanat F, Rauseo AM, Haile A, Xie X, Klebert MK, Suessen T, Middleton WD, Shi PY, Krammer F, Teefey SA, Diamond MS, Presti RM, Ellebedy AH. Turner JS, et al. Among authors: o halloran ja. Nature. 2021 Aug;596(7870):109-113. doi: 10.1038/s41586-021-03738-2. Epub 2021 Jun 28. Nature. 2021. PMID: 34182569 Free PMC article.
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans.
Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, Hansen L, Haile A, Klebert MK, Pusic I, O'Halloran JA, Presti RM, Ellebedy AH. Turner JS, et al. Among authors: o halloran ja. Nature. 2021 Jul;595(7867):421-425. doi: 10.1038/s41586-021-03647-4. Epub 2021 May 24. Nature. 2021. PMID: 34030176
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.
Alsoussi WB, Malladi SK, Zhou JQ, Liu Z, Ying B, Kim W, Schmitz AJ, Lei T, Horvath SC, Sturtz AJ, McIntire KM, Evavold B, Han F, Scheaffer SM, Fox IF, Mirza SF, Parra-Rodriguez L, Nachbagauer R, Nestorova B, Chalkias S, Farnsworth CW, Klebert MK, Pusic I, Strnad BS, Middleton WD, Teefey SA, Whelan SPJ, Diamond MS, Paris R, O'Halloran JA, Presti RM, Turner JS, Ellebedy AH. Alsoussi WB, et al. Among authors: o halloran ja. Nature. 2023 May;617(7961):592-598. doi: 10.1038/s41586-023-06025-4. Epub 2023 Apr 3. Nature. 2023. PMID: 37011668
Immune phenotypes that predict COVID-19 severity.
Liechti T, Iftikhar Y, Mangino M, Beddall M, Goss CW, O'Halloran JA, Mudd P, Roederer M. Liechti T, et al. Among authors: o halloran ja. Res Sq. 2022 Mar doi: 10.21203/ Preprint. Res Sq. 2022. PMID: 35291290 Free PMC article. Updated.
HIV and obesity: updates in management strategies.
Parra-Rodriguez L, O'Halloran JA. Parra-Rodriguez L, et al. Among authors: o halloran ja. Curr Opin HIV AIDS. 2023 Mar 1;18(2):68-74. doi: 10.1097/COH.0000000000000781. Epub 2023 Jan 16. Curr Opin HIV AIDS. 2023. PMID: 36644952 Review.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Hardt K, et al. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Lancet Infect Dis. 2022. PMID: 36113538 Free PMC article. Clinical Trial.
76 results